Patents for A61P 35 - Antineoplastic agents (221,099)
02/2008
02/12/2008CA2208206C Composition for treating tumors comprising lactose and a saccharide conjugate of a cytotoxic phenolic compound
02/12/2008CA2156273C Allogeneic vaccine and methods to synthesize same
02/12/2008CA2133982C Ligand for the c-kit receptor and methods of use thereof
02/12/2008CA2131729C Helicobacter pylori proteins useful for vaccines and diagnostics
02/08/2008CA2596467A1 Dendroaspis natriuretic peptide
02/07/2008WO2008016893A1 Smac peptidomimetics useful as iap inhibitors
02/07/2008WO2008016890A1 Antitumorigenic drug combination
02/07/2008WO2008016793A2 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
02/07/2008WO2008016702A2 Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
02/07/2008WO2008016700A2 N-oxide compounds for therapeutics uses
02/07/2008WO2008016661A2 Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
02/07/2008WO2008016660A2 Imidazoacridine compounds for treating leukemias
02/07/2008WO2008016547A2 Aurora kinase inhibitors from an encoded small molecule library
02/07/2008WO2008016282A1 Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and rheb
02/07/2008WO2008016281A1 Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and raptor
02/07/2008WO2008016187A1 Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound
02/07/2008WO2008016175A1 Activator for peroxisome proliferator activated receptor
02/07/2008WO2008016172A1 Metastasis inhibitor
02/07/2008WO2008016141A1 Kif-derived peptide capable of binding to hla-a24 molecule
02/07/2008WO2008016139A1 Fluorescent oleamide derivative and use thereof
02/07/2008WO2008016131A1 Fused heterocyclic compound
02/07/2008WO2008016107A1 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
02/07/2008WO2008016078A1 Method of proliferating lak cell
02/07/2008WO2008016006A1 Compound having cyclic group bound thereto through spiro binding and use thereof
02/07/2008WO2008015942A1 Therapeutic agent for neuroblastoma, method for screening for the therapeutic agent, and method for determination of prognosis of neuroblastoma
02/07/2008WO2008015867A1 Method for activating and stabilizing dissolved hydrogen in water
02/07/2008WO2008015841A1 Kinase-inhibiting fused protein and pharmaceutical composition
02/07/2008WO2008015794A1 Boronated quinazoline derivative
02/07/2008WO2008015423A1 Quinoline and quinoxaline n-oxides as chk-1 inhibitors
02/07/2008WO2008015383A2 Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
02/07/2008WO2008015340A2 Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapuetic application thereof
02/07/2008WO2008015315A1 Thiourea-containing medicinal compounds for treating cancer in association with chemotheraputic agents or ionizing or non-ionizing radiation
02/07/2008WO2008015267A1 A method for the in vitro screening of anti-cancer compounds that inhibits sk3 activity, and said anti-cancer compounds
02/07/2008WO2008015265A1 Anthracen derivatives and their use for the treatment of benign and malignant tumorous diseases
02/07/2008WO2008015250A1 Pyrimidine compounds for combating pathogenic fungi and cancer
02/07/2008WO2008015139A2 Inhibitors of zinc proteases thioaryl substituted and their use
02/07/2008WO2008014779A1 Method for establishing the sensitivity of tumours to capecitabin and test kit
02/07/2008WO2008014668A1 Attenuated salmonella carrying effective plasmid and its antitumorigenic use
02/07/2008WO2008014603A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
02/07/2008WO2008014583A1 Cancerous disease modifying antibodies
02/07/2008WO2008014564A1 Methods and compositions for inhibiting angiogenesis
02/07/2008WO2008014563A1 Methods and compositions for promoting activity of anti-cancer therapies
02/07/2008WO2008002544A3 Unit dosage forms of temozolomide
02/07/2008WO2007143483A3 Combination of pazopanib and lapatinib for treating cancer
02/07/2008WO2007138472A3 Triazolopyridazine derivatives
02/07/2008WO2007135546A3 TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
02/07/2008WO2007124734A3 Compounds a-r-x for the manufacture of pharmaceutical preparations
02/07/2008WO2007121484A3 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
02/07/2008WO2007117398B1 Non-peptidic molecules for detecting and treating tumors
02/07/2008WO2007109596A3 Heteroaryl dihydroindolones as kinase inhibitors
02/07/2008WO2007103308A3 Heterobicyclic pyrazole compounds and methods of use
02/07/2008WO2007072042A3 Identification of apoptosis inducing proteins
02/07/2008WO2006136564A9 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
02/07/2008WO2005117999A3 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
02/07/2008US20080033170 Novel compounds
02/07/2008US20080033165 2-(3-(2-phenyloxazolidin-4-on-3-yl)-4-(2-styryl)-azetidin-2-on-1-yl) alkanedioic acid derivatives and corresponding alkoxyalkanoic acid derivatives; treating psychological disorders, cardiovascular disorders
02/07/2008US20080033061 Cation conducting gabaa receptors and their use
02/07/2008US20080033057 Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
02/07/2008US20080033056 Xanthohumol based protein kinase modulation cancer treatment
02/07/2008US20080033039 Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer
02/07/2008US20080033035 Animal extract from a deep-water sponge of the genus Leiodermatium collected in the US and Bahamas; polyene macrolide antibiotics; multidrug resistant cancers; potentinhibition of mitosis by causing a G2/M block; anticarcinogenic, -tumor, -proliverative and -inflammatory agents; autoimmune diseases
02/07/2008US20080033012 Enzyme inhibitors
02/07/2008US20080033007 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy
02/07/2008US20080033004 Synthesis of grossularines-1 and analogs thereof and method of use
02/07/2008US20080033003 Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents
02/07/2008US20080033001 Derivatives of Variolin B
02/07/2008US20080033000 Identification of CDKI pathway inhibitors
02/07/2008US20080032999 viricides for treating a hepatitis C virus infection
02/07/2008US20080032998 Pyrazolopyrimidines, a process for their preparation and their use as medicine
02/07/2008US20080032997 (5S)-5-methyl-5-({[6-[2-(trifluoromethyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)imidazolidine-2,4-dione; asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis (such as rheumatoid arthritis and osteoarthritis), atherosclerosis, cancer
02/07/2008US20080032991 2, 8-disubstituted Naphthyridine Derivatives
02/07/2008US20080032987 Quercetin-containing compositions
02/07/2008US20080032983 Ortho-Substituted N'-Benzylidene-(3-Hydroxyphenyl)Acethydrazides
02/07/2008US20080032981 Aryl n-cyanoguanidines and methods related thereto
02/07/2008US20080032980 1-Carbonyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles such as 1-acetyl-4-(1-{[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)piperazine trifluoroacetate that are useful for treating cancer
02/07/2008US20080032979 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
02/07/2008US20080032977 Alkyne-substituted pyridone compounds and methods of use
02/07/2008US20080032974 Compounds and therapeutical use thereof
02/07/2008US20080032971 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
02/07/2008US20080032969 Novel compounds
02/07/2008US20080032960 PI3 kinase antagonists
02/07/2008US20080032957 liver, lung, skin, breast, brain glioma, colon and rectum, stomach, head and neck, leukemia, malignant lymphoma, sarcoma, malignant melanoma, myeloma, and metastasis cancers
02/07/2008US20080032956 2-Ethyl and 2-Ethylidene-19-Nor-Vitamin D Compounds
02/07/2008US20080032954 Vascular Damaging Agents for Administration as an Intravenous Infusion
02/07/2008US20080032948 administering folic acid, methylmalonic acid lowering agent (vitamin B12, hydroxycobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-cobalamin perchlorate, azidocobalamin, cobalamin, cyanocobalamin, or chlorocobalamin), then pemetrexed disodium
02/07/2008US20080032943 Using concentration of cancer-associated gene products as diagnostic tool in detection of thyroid cell proliferative disorders
02/07/2008US20080032940 Methods for reducing anthracycline-induced toxicity
02/07/2008US20080032939 Iridoid-saccharide compound and method of using same
02/07/2008US20080032935 Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
02/07/2008US20080032927 Treatment of development-related disorders
02/07/2008US20080032384 Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
02/07/2008US20080032320 Method of Screening Compound Capable of Accelerating or Inhibiting Apoptosis, Apoptosis Accelarator and Apoptosis Inhibitor
02/07/2008US20080031936 Immunostimulatory nucleic acid molecules
02/07/2008US20080031907 Cosmetic and pharmaceutical foam
02/07/2008US20080031900 Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
02/07/2008US20080031894 Beta acid based protein kinase modulation cancer treatment
02/07/2008US20080031893 Acacia based protein kinase modulation cancer treatment
02/07/2008US20080031888 Tumor antigens
02/07/2008US20080031887 Conjugates for inducing targeted immune responses and methods of making and using same
02/07/2008US20080031886 Viruses for the treatment of cellular proliferative disorders